Does the Stockholm3 blood test catch more aggressive prostate cancers than PSA?
Yes. In a study of 12,670 men, the Stockholm3 blood test caught 90 percent of aggressive prostate cancers found within two years, compared with 74 percent for the standard PSA test. Of 443 men with an aggressive cancer, Stockholm3 missed 43 and PSA missed 116. It did this without a big jump in false alarms: 11 percent of men without aggressive cancer got a false positive on Stockholm3, versus 10 percent on PSA.
For decades, the main tool for prostate cancer screening has been the PSA test. PSA stands for prostate-specific antigen, a protein your prostate makes. A high level can be a warning sign. The problem is that PSA on its own is a blunt instrument. It misses some dangerous cancers and flags many harmless ones, sending men to biopsies they never needed.
This study tested a different approach. Instead of relying on PSA alone, researchers used the Stockholm3 test. It is a blood test that combines PSA with genetic markers, other blood proteins, and personal risk factors. Men with a concerning result on either test were randomly assigned to a standard biopsy or to an MRI scan, which takes detailed pictures of the prostate, followed by biopsies. The goal was to find the cancers that can spread and kill, while leaving slow-growing ones alone.
What the data show
The differences were large. Across 12,670 men aged 50 to 74, the Stockholm3 test caught 90 percent of aggressive cancers, the kind doctors call clinically significant. Standard PSA caught fewer. At a cutoff of 3 nanograms per milliliter, PSA found 74 percent, meaning it missed about 1 in 4 of the serious cancers.
The most important part is what did not happen. The better detection did not flood the system with false positives. Specificity, which measures how well a test avoids false alarms in healthy men, was similar between the two approaches. In plain terms, the newer test found more real cancers without wrongly worrying many more men.
Dr. Kumar’s Take
I find this encouraging, and I want to explain why. The knock on prostate screening has never been that doctors cannot find cancer. It is that PSA finds too much of the wrong kind. It catches slow-growing cancers that would never have harmed a man, while sometimes missing the aggressive ones. That leads to needless biopsies, anxiety, and treatment side effects like incontinence.
A test that improves detection while holding false positives steady is exactly what this field has needed. In this study, the smarter blood test pointed to fewer unnecessary biopsies and fewer missed dangerous cancers, and catching those cancers early is when they are most treatable. This is a two-year follow-up, so longer data on lives saved are still needed. But the direction here is promising.
Why this matters for men over 50
Prostate cancer is common, and most cases grow so slowly that they never threaten a man’s life. The real challenge is telling those apart from the aggressive cancers that spread. Get it wrong in one direction and you treat a harmless tumor with surgery or radiation. Get it wrong in the other and you miss a killer.
By adding genetic and protein markers to PSA, the Stockholm3 approach sharpens that judgment before anyone picks up a biopsy needle. The MRI step adds another layer, showing exactly where a suspicious area sits. Together they help doctors act on the cancers that count and step back from the ones that do not.
How this study was done
This was a population-based screening study, meaning it invited men from the general population in the Stockholm region rather than only those already worried about symptoms. Only about 25 percent of invited men took part, and the group was mostly Swedish or European, so the results may not apply equally to every population. The 12,670 participants spanned ages 50 to 74, the window when prostate cancer risk starts to climb.
Each man’s blood test result decided whether he went on to biopsy, with or without MRI, and the researchers then compared how well the Stockholm3 approach and standard PSA identified aggressive cancers. Because everyone came from the same group, the comparison is a fair head-to-head. The two-year follow-up gives an early read, though longer tracking will show how these detection gains translate into fewer deaths over time.
Practical Takeaways
- If you are a man between 50 and 74 thinking about prostate screening, ask your doctor whether a multivariable blood test like Stockholm3 is available in your area, since it may reduce unnecessary biopsies.
- Do not treat a single PSA number as the whole story, because PSA alone missed about 1 in 4 aggressive cancers in this study.
- If your screening result is concerning, ask about an MRI before agreeing to a biopsy, as imaging can help pinpoint whether a biopsy is truly needed.
- Talk through your personal risk factors, since clinical factors and genetic risk feed into newer tests like Stockholm3.
Related Studies and Research
- Is testosterone safe for men after prostate cancer surgery?
- A plant-based diet is linked to lower heart disease risk over 20 years
FAQs
What is the difference between the Stockholm3 test and a regular PSA test?
A regular PSA test measures one thing, the level of prostate-specific antigen in your blood. The Stockholm3 test measures PSA too, but it also adds several other blood proteins, genetic markers, and personal details like age and family history. It then combines all of this into a single risk estimate. The idea is that looking at many signals at once gives a clearer picture of who truly has a dangerous cancer, rather than relying on one number that can mislead.
Does a better test mean more men will get biopsies?
Slightly more, in raw numbers. In this study, 1,689 men screened positive on Stockholm3 versus 1,530 on PSA, and false positives were 1,289 versus 1,203. Specificity stayed similar, so there was no wave of new false alarms. The authors’ decision curve analysis, which weighs cancers found against biopsies done, still favored Stockholm3 across a range of biopsy thresholds, pointing to fewer unnecessary biopsies for each aggressive cancer caught.
Should I stop getting PSA tests based on this study?
Not on your own. PSA is still a widely used and valuable tool, and this study builds on it rather than throwing it out. The Stockholm3 test actually includes PSA as one of its ingredients. What this research suggests is that adding more information can make screening smarter. The right move is to discuss your options with your doctor, who can weigh your age, risk factors, and what tests are available where you live.
Bottom Line
In a large population-based study of 12,670 men, a blood test that combines PSA with genetic and protein markers caught 90 percent of aggressive prostate cancers found within two years. Standard PSA, at a cutoff of 3 ng/mL, caught 74 percent. Crucially, the smarter approach did this with only a small rise in false alarms, 11 percent versus 10 percent. For men weighing prostate cancer screening, it points toward catching more of the dangerous cancers early.
